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Purpose: To assess the effects of retro-orbital (RO) injection of fluorescein isothiocyanate dextran (FITC-dextran) for
observing mouse retinal vessels.
Methods: Oxygen-induced retinopathy (OIR) was induced in 7-day postnatal (P7) C57BL/6J mice by exposing them to
a 75% oxygen atmosphere for 5 days and then returning them to room air at P12. At P17, 45 P17 OIR mice and 12 normal
mice received an RO injection of FITC-dextran. Five P17 OIR mice were perfused with FITC-dextran via the left ventricle.
Retinal ﬂatmounts were viewed under a ﬂuorescence microscope and a confocal microscope. Following RO injection or
left ventricular (LV) perfusion, the areas of neovascularization, as well as the total retina areas, were measured and analyzed
using Image Pro-Plus 5.1 software.
Results: The suitable volume of FITC-dextran for RO injection to observe the retinal vessels of a P17 OIR mouse was
0.05 ml, the 5% volume required to achieve similar results by administering FITC-dextran using LV perfusion. The total
retinal vessels in P17 OIR mice could be fully observed under a ﬂuorescence microscope 3 s after RO injection of FITC-
dextran. Our study showed that RO injection of FITC-dextran was suitable for observing the retinal vessels of all postnatal
mice. There was no significant difference in evaluating retinal neovascularization between RO injection and LV perfusion
of FITC-dextran (p>0.05).
Conclusions: Retro-orbital injection of FITC-dextran is an economical method for observing retinal vessels in mice, when
compared with LV perfusion of FITC-dextran.
During the physiologic development of the retina and the
pathophysiological  progression  of  retinal  vessel–related
diseases, such as retinopathy of prematurity (ROP), diabetic
retinopathy,  and  retinal  vessel  occlusion,  the  changes  in
retinal  vessels  are  observed  to  understand  retinal
vascularization. The retinal vascular abnormities of ROP can
be studied in a well described oxygen-induced retinopathy
(OIR) model [1]. Some substances, such as isolectin B4 [2],
collagen  IV  [3],  and  fluorescein  isothiocyanate  dextran
(FITC-dextran)  [4],  are  used  to  observe  retinal  vessels.
Studies  show  that  high-molecular-weight  FITC-dextran
(2×106) remaining in the vasculature without diffusion is a
successful approach for observing mouse retinal vessels; in
contrast, low-molecular-weight FITC-dextran (4×104-5×104)
is not suitable as it leaks out of the vasculature [5]. The current
method for sending FITC-dextran to mouse retinas is left
ventricular  (LV)  perfusion  [6,7].  The  problem  is  that  LV
perfusion requires the researcher to perform many operations
and these operations increase the mortality rate among the
subject mice.
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Previous studies [8,9] have shown that retro-orbital (RO)
injection is a good and simple alternative for delivering low-
molecular-weight substances such as viruses and radiotracers
in vivo of mice. Researchers detected the injected materials
later in organs such as the liver, lungs, and heart, proving that
substances absorbed through the retro-orbital sinus could be
widely  distributed  by  the  blood  circulatory  system.  RO
injection  was  also  used  for  middle-molecular-weight
fluorescein  isothiocyanate  BSA  (7×104)  to  observe  liver
tissues [10]. There are numerous anastomoses in the mouse
orbital venous sinus [11], and the fenestrae of the mouse
venous sinus is larger than the fenestrae of the microvascular
wall [12]. Thus, we wondered whether high-molecular-weight
FITC-dextran (2×106) could also be sent with RO injection to
the retinal vessels. In this study, we injected FITC-dextran into
the orbital venous sinus of OIR and normal neonatal mice to
evaluate whether such injection allowed us to fully observe
the retinal vessels and to compare the effects of RO injection
with the effects of LV perfusion.
METHODS
Animals: All animal experiments adhered to the Association
for  Research  in  Vision  and  Ophthalmology  (ARVO)
statement for the Use of Animals in Ophthalmic and Vision
Research and were approved by the Animal Care and Use
Committee of the Zhongshan Ophthalmic Center, Sun Yat-
sen University, Guangzhou, China.
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3566C57BL/6J  timed-pregnant  mice  were  purchased  from
Southern Medical University, Guangzhou, China. The mice
were housed in a specific pathogen-free animal facility at the
Ophthalmic Animal Laboratory of the Zhongshan Ophthalmic
Center. Feed and distilled water were available to the mice ad
libitum, and fresh cages were provided on a weekly schedule.
Oxygen-induced retinopathy model: The OIR mouse model
was induced according to the protocol described previously
[1]. Briefly, to induce retinal neovascularization, at postnatal
day 7 (P7), mouse pups and their nursing dams were exposed
to a 75%-oxygen atmosphere for 5 days and then returned to
room air at P12. The retinal neovascularization of the OIR
mice reached its peak at P17 [13]. The nursing dams were
rotated from high oxygen to room air every 24 h to prevent
oxygen toxicity.
Retro-orbital injection of fluorescein isothiocyanate dextran:
Before injection, FITC-dextran (FD2000S; Sigma-Aldrich,
St.  Louis,  MO)  was  dissolved  in  ultrapure  water  at  a
concentration of 50 mg/ml, centrifuged at 10,000× g for 5 min,
and collected as the supernatant. FITC-dextran was protected
from light during the preparation.
P17 OIR mice, weighing 5.55–5.75 g, were anesthetized
with an intraperitoneal (IP) injection of 10% chloral hydrate
(2.5 ml/kg). The lateral canthus of the left orbit was chosen as
the injection point. Gentle pressure with two fingers of the
right hand was applied to the peri-orbital area to expose the
mouse’s left eye. A 27-gauge needle with a 1 ml syringe
attached gently pierced about 2–3 mm into the mouse’s orbital
venous sinus with the bevel on the needle facing forward at a
45° angle [8], and then different volumes of FITC-dextran
were injected.
To  investigate  the  volume  of  injected  FITC-dextran
needed  to  observe  the  mouse  retinal  vessels,  one  of  six
different volumes of FITC-dextran (0.01 ml, 0.02 ml, 0.03 ml,
0.04 ml, 0.05 ml, or 0.10 ml) was injected into each of three
P17 OIR mice, respectively, for a total of 18 P17 OIR mice
injected during this step.
To investigate the optimal time for the enucleated eye, 27
P17 OIR mice eyes were enucleated at different elapsed time
points after RO injection of 0.05 ml FITC-dextran (1 s, 2 s, 3
s, 5 s, 1 min, 5 min, 1 h, 2 h, and 5 h).
To evaluate whether the RO injection was suitable for a
neonatal mouse, eyes from normal postnatal mice (n=12) were
enucleated 5 min after RO injection of FITC-dextran at P0,
P2, P8, and P17. The mice were injected with 0.02 ml, 0.02 ml,
0.04 ml, or 0.06 ml of FITC-dextran, respectively, depending
on their weight (1.20 g, 1.74 g, 4.22 g, or 7.69 g).
Left  ventricular  perfusion  of  fluorescein  isothiocyanate
dextran: Five P17 OIR mice, weighing 5.55 g–5.75 g, were
anesthetized with an IP injection of 10% chloral hydrate. The
thoracic cavity was opened to expose the pumping heart, and
the right atrium was cut with scissors to interrupt the mouse’s
blood circulatory flow, ensuring that FITC-dextran about to
be injected in vivo into the left ventricle was not diluted by
blood returning from the mouse’s lungs.
One ml of 50 mg/ml concentration of FITC-dextran was
injected  into  the  left  ventricle.  The  mouse’s  eyes  were
enucleated after a marked green coloration appeared on the
front paws and tongue, indicating successful perfusion [6].
Retinal  flatmounts:  Retinal  ﬂatmounts  were  prepared
according to the method described previously [14]. Briefly,
the enucleated eyes were fixed in 4% paraformaldehyde for
40  min  at  room  temperature.  The  cornea,  iris,  lens,  and
vitreous  were  gently  removed  under  a  stereomicroscope
(Mz6; Leica, Wetzlar, Germany). Four to six radial incisions
were made in the dissected retina, and it was flattened with a
coverslip.
The retinal flatmounts were photographed at 50× original
magnification with fluorescence microscopy (Zeiss Axioplan
2 imaging, Gottingen, Germany). The combined exposure
time of the retinal flatmounts was 1.5 s. The superficial and
deep vessels of the retina in each P17 OIR mouse were viewed
under a confocal microscope (LSM 510 META; Carl Zeiss,
Jena,  Germany).  The  retinal  segments  were  merged  to
generate an image of the total retina (Photoshop CS4; Adobe
Systems Inc., San Jose, CA).
Quantification of retinal neovascularization: To compare the
success of injecting FITC-dextran to facilitate observation of
retinal  neovascularization  (NV)  using  the  RO  injection
method and the LV perfusion method, retinal flatmounts of
three P17 mice in each group were used to quantify the area
of retinal NV. Retinal flatmounts of P17 normal air mice (the
control group) were also compared to those of the OIR mice
(the OIR group). The retinal NV and the total retina were
measured by outlining the corresponding areas and analyzed
using  Image  Pro-Plus  5.1  software  (Media  Cybernetics
Company, Silver Spring, MD), using the methods previously
described [15].
Statistical analysis: Statistical analysis was performed using
SPSS software version 16.0 (SPSS, Inc., Chicago, IL). The
data, showing the percentages of retinal neovascularization
quantified by comparing the area of retinal neovascularization
with the total area of the retina, were reported as the mean
±standard  deviation  (SD)  one-way  ANOVA  used  for
multiple-group comparison; an unpaired Student t test was
used for the RO injection group and the LV perfusion group.
A p value <0.05 was considered statistically significant.
RESULTS
Retro-orbital injection of fluorescein isothiocyanate dextran
in C57BL/6J mouse: The efficacy of RO injections varied
depending on the amount of FITC-dextran injected. The RO
injections of 0.01 ml, 0.02 ml, 0.03 ml, and 0.04 ml of FITC-
dextran produced enhancements of small retinal vessels and
neovascular tufts that were too weak to be fully shown with
fluorescence, whereas RO injections of 0.05 ml and 0.10 ml
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3567of FITC-dextran enhanced those vessels and tufts sufficiently
to be fully observed (Figure 1).
After the RO injection of 0.05 ml of FITC-dextran, the
superficial  and  deep  vascular  plexuses  of  the  retina  were
observed clearly under a confocal microscope; the structure
of the neovascular tufts (arrow) was also distinguished (Figure
2). The superficial vascular plexus showed many neovascular
tufts  and  large  retinal  vessels.  The  deep  vascular  plexus
showed small retinal vessels.
The efficacy of the RO injections also varied with the time
elapse  between  the  injection  and  the  observation.  The
fluorescence of small retinal vessels and neovascular tufts
were too weak to be observed at 1 s and 2 s after the RO
injection of 0.05 ml of FITC-dextran, but the small retinal
vessels and neovascular tufts were fully observed from 3 s to
5 h after the RO injection (Figure 3).
The mouse’s superficial retinal vascular structures grew
outward radially after birth, from the central optic nerve to the
retinal periphery. As shown in Figure 4, the fluorescence of
the normal retinal vascular plexus was observed around the
optic nerve in a P0 mouse and at the edge of the full retina in
a P8 mouse. Figure 4 also shows the normal large and small
retinal vessels of a P17 mouse.
Comparison of the left ventricular perfusion and retro-orbital
injection methods: The LV perfusion protocol usually called
for injecting 1 ml of FITC-dextran concentrated to 50 mg/ml
into each mouse heart, whereas the RO protocol injected only
0.05 ml per mouse.
Each LV perfusion surgical procedure took about 4 min
and required four steps: providing anesthesia, opening the
thoracic cavity, cutting the right atrium, and filling the left
ventricle to initiate perfusion. The RO injection took about 30
s and required only two steps: anesthesia and injection into
the orbital venous sinus.
The success rates of the RO and LV procedures were
100%. The time for the enucleated eyes for LV perfusion
ranged from 1 min to 2 min, because the mouse died about 1
min after LV perfusion. However, the time for enucleated eyes
for RO injection ranged from 3 s to 5 h. In our study, mouse
recovery from general anesthesia was about 70 min, and no
complications were found after RO injection of 0.05 ml of
FITC-dextran.
The  percentage  of  retinal  neovascularization  in  the
control group (Figure 5A) and the OIR group (Figure 5B,C)
was compared, and a significant increase in the OIR group
was  observed  (F=0.007,  p=0.001<0.05;  Figure  5D).  No
significant  difference  in  the  percentage  of  retinal
Figure 1. Representative retinal flatmounts from a P17 oxygen-induced retinopathy mouse after a retro-orbital injection of different volumes
of fluorescein isothiocyanate dextran (FITC)-dextran. The fluorescence of 0.01–0.04 ml of FITC-dextran was too weak, while the fluorescence
of 0.05 ml or 0.10 ml was fully observed. Original magnification: 50×.
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3568neovascularization was found between the RO group and the
LV group (0.1030±0.0008 and 0.0997±0.0037, respectively;
t=2.132, p=0.208 >0.05; Figure 5D).
DISCUSSION
Previous studies have shown that the recommended injection
volume for an adult mouse is ≤0.15 ml [16], but no studies
have established a safe injection volume for a P17 OIR mouse.
Our study found that an RO injection of 0.05 ml of FITC-
dextran  satisfactorily  facilitated  the  fluorescence  of  the
superficial and deep vascular plexuses in a P17 OIR mouse,
and the mice lived without accident; the optimal and safe
volume for an RO injection of 50 mg/ml of FITC-dextran for
P17 OIR mouse was 0.05 ml. Thus, we considered that the
Figure 2. The superficial and deep vascular plexuses of the retina in a P17 oxygen-induced retinopathy mouse after a retro-orbital injection
of fluorescein isothiocyanate dextran (FITC)-dextran. A: The retinal flatmount of a P17 oxygen-induced retinopathy mouse shows the
fluorescence of small retinal vessels, avascular areas, and neovascular tufts. B: Original magnification: 50×. The superficial neovascular tufts
(Arrow, C) and the deep vascular plexus (D) can be observed. Original magnification: 100×.
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3569optimal and safe volume for an RO injection of 50 mg/ml of
FITC-dextran for a mouse should be in accordance with the
mouse weight and is about 0.009 ml/g (0.05 ml/5.55 g, the
weight of P17 OIR mice).
A previous study indicated that the basal heart rate of a
C57BL/6J mouse is more than 500 beats per min (bpm) [17],
meaning that one complete circuit of blood takes less than
0.125 s. In our study, the fluorescence of flatmounted retinal
vessels was not fully observed until 3 s after injection. This
result indicates that 0.05 ml of FITC-dextran might not be
fully absorbed to the mouse’s blood circulation system at 1 s
and 2 s after the RO injection. The small retinal vessels and
neovascular tufts were still seen at 5 h after the RO injection.
Therefore, the recommended period for enucleating a mouse’s
eye ranges from 3 s to 5 h after an RO injection.
FITC-dextran  has  been  dissolved  in  PBS  in  some
previous  studies  [1].  In  our  study,  the  FITC-dextran  was
dissolved  in  ultrapure  water  according  to  the  product
information for FITC-dextran provided by the manufacturer.
Yardeni  et  al.  [16]  reported  administering  retro-orbital
injections  can  reliably  deliver  volumes  up  to  0.01  ml  in
neonatal mice. The mouse retro-orbital sinus area is large with
Figure 3. Time course of fluorescence of a P17 oxygen-induced retinopathy mouse after a retro-orbital injection of fluorescein isothiocyanate
dextran (FITC)-dextran. The fluorescence of FITC-dextran in small retinal vessels was too weak at 1 s and 2 s, but the retinal vessels were
fully observed at 3 s and could still be seen at 5 h. Original magnification: 50×.
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3570a substantial amount of blood flow [16], and the fenestrae of
the orbital venous sinus is very large, which make a small
volume (0.01 ml) of pure water be absorbed quickly (not more
than 3 s) into the blood circulation of a P0 mouse. Moreover,
there are potential spaces in the eye orbit for many fats. Thus,
a small volume of pure water injected into the retro-orbit one
time will not affect the retinal or retro orbital tissues very
much compared with PBS (data not shown); especially in our
study, the mice were sacrificed, and the eyes were enucleated
5 min after an RO injection of pure water. Therefore, using
pure water to dissolve FITC-dextran did not affect the results
in  our  study.  However,  when  multiple  RO  injections  are
performed to obtain real-time retinal vessel images under a
Micron II or III microscope without sacrificing the mice, PBS
as  an  isotonic  vehicle  is  a  better  choice  than  pure  water,
because multiple injections of pure water into the retro-orbit
might cause some slight localized micro-cellular damages.
One study showed that an RO injection is suitable for a
neonatal mouse [16], but no report has confirmed that the
orbital venous sinus of a neonatal mouse is developed enough
to  absorb  high-molecular-weight  FITC-dextran.  Figure  4
shows  the  fluorescence  of  retinal  vessels  in  a  P0  mouse,
Figure 4. Retro-orbital injection of fluorescein isothiocyanate dextran (FITC)-dextran in newborn to P17 normal air mice. The superficial
retinal vascular plexus grew outward from the optic nerve head (P0) to the peripheral tissue (P8), and the retinal vascular plexus of a P17
mouse was observed. Original magnification: 50×.
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3571indicating that the fenestrae of the orbital venous sinus are
large enough to absorb high-molecular-weight FITC-dextran.
In addition, we observed the fluorescence of retinal vessels in
P2, P8, and P17 normal mice. Therefore, RO injection of
FITC-dextran  is  suitable  for  all  postnatal  mice.  Previous
studies also used many different types of injection needles,
including 31-gauge or 32-gauge needles in newborn mice
[9,18]. We found that a 27-gauge needle was suitable for
newborn mice and all postnatal mice. As a 27-gauge needle is
easy to find, RO injection of FITC-dextran does not require
special equipment.
In our study, a 0.05 ml RO injection of FITC-dextran
produced as good enhancement for observing retinal vessels
as a 1 ml LV perfusion, because most of the FITC-dextran in
a LV perfusion flows out of the right atrium after one rapid
circuit through the mouse’s body. Compared with the LV
perfusion method, the RO injection of the FITC-dextran for
observing mouse retinal vessels has the following advantages:
economical (an RO injection uses only 5% as much FITC-
dextran as LV perfusion), simple (the RO injection procedure
is easier than that of LV perfusion).
In  summary,  RO  injection  of  high-molecular-weight
FITC-dextran is suitable for all postnatal mice, and is an
economical method for observing mouse retinal vessels, when
compared with LV perfusion of FITC-dextran.
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